SPORE in Ovarian Cancer Honored
The research efforts of the Dana-Farber/Harvard Cancer Center SPORE in Ovarian Cancer were honored on Thursday, September 20th at the Omni Parker House in Boston.
The third annual Teal Ribbon ceremony, commemorating National Ovarian Cancer Awareness Month, was sponsored by OvarianCancerAwareness.org, a Coalition of health care organizations and advocates committed to using the power of information to support the early detection and cure of ovarian cancer. Boston Mayor Thomas Menino also received an award for his efforts to promote awareness of ovarian cancer.
Barbara O’Brien, an ovarian cancer survivor and President of the Massachusetts Chapter of the National Ovarian Cancer Coalition presented the Teal Ribbon Award saying, “In 1998 it was our dream of having an Ovarian Cancer SPORE here in Boston and in 2004 that dream came true. The researchers at the DF/HCC SPORE in Ovarian Cancer SPORE are making progress everyday in the fight against ovarian cancer.” Accepting on behalf of the SPORE was Dr. Daniel Cramer.
“Each year, we see far too many women succumb to ovarian cancer but we also see enormous progress being made in the significant but achievable task of eradicating this disease,” said Dr. Daniel Cramer, Principal Investigator for the DF/HCC SPORE. “On behalf of the Ovarian Cancer SPORE researchers, I am delighted to be accepting an award that acknowledges the strides that have been made while emphasizing the work that still lies ahead.”
“The significance of the Teal Ribbon awards is that they represent hope and progress in an area that is so often dominated by grim statistics and very sad stories,” said Bill Shea of the Ovarian Cancer Education Awareness Network (OCEAN). “It is true that ovarian cancer is a formidable disease but it is also one that can be cured with early detection and continued research which is why the contributions of both Mayor Menino and SPORE at Dana-Farber/Harvard Cancer Center are to be so enthusiastically applauded.”
Ovarian cancer is the second most common gynecological cancer in women, but ranks first (above endometrial cancer) in cancer deaths. Approximately 20,180 new ovarian cancers will be diagnosed in the United States in the year 2006 and about 15,310 women will die from this disease. The high mortality rate stems from an overall lack of early symptoms or screening methods for the disease. As a result, most ovarian cancer patients are diagnosed with advanced stage disease.
The DF/HCC SPORE in ovarian cancer is focused on finding new ways to prevent, diagnose and treat ovarian cancer. Ovarian SPORE projects include studies to identify modifiable environmental risk factors associated with ovarian cancer and their interaction with the genotype, research to identify the molecular basis of carcinogenesis in ovarian cancer, and the design of novel immunotherapies to treat women with ovarian cancer.